News | May 30, 2022
NHA launches online public dashboard for Ayushman Bharat Digital Mission (ABDM)
The ABDM public dashboard is a one-stop solution for information on the mission’s progress up to state/UT level
The ABDM public dashboard is a one-stop solution for information on the mission’s progress up to state/UT level
Multiples is the first private equity (PE) investor in the company
The launch is yet another first of its kind innovation in India
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
_256_384.jpg)
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
This marks the second indication for which gumokimab has gained NDA review acceptance
Subscribe To Our Newsletter & Stay Updated
